Compare Dicks Sporting Goods Inc (DKS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Novavax Inc — how do they compare? Dicks Sporting Goods Inc trades at $202.29 (market cap $18.35B), while Novavax Inc trades at $7.89 (market cap $1.31B). The key difference: Dicks Sporting Goods Inc is far larger — about 14× Novavax Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| DKS | NVAX | |
|---|---|---|
Market Cap | $18.35B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $11.19 |
52-Week Low | $187.78 | $6.22 |
Enterprise Value | $25.14B | $889.30M |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
